Scribd Logo
Upload

Welcome to Scribd!

  • 120 views

    Astrazeneca Summary

    Uploaded by

    sommer_ronald5741
    AstraZeneca (AZN) is a major player in the biotechnology and drug industry with a rich product line focusing on six healthcare areas. In fiscal year 2009, AZN's top drugs - Nexium, Crestor, Symbicort, Arimidex, Seroquel, and Synagis - accounted for over 60% of the company's $32.8 billion in total sales. AZN has experienced continued sales and earnings growth in recent years and maintains a strong balance sheet and profitability ratios above historical averages.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOCX, PDF, TXT or read online from Scribd

    Astrazeneca Summary

    Uploaded by

    sommer_ronald5741
    120 views1 page
    AstraZeneca (AZN) is a major player in the biotechnology and drug industry with a rich product line focusing on six healthcare areas. In fiscal year 2009, AZN's top drugs - Nexium, Crestor, Symbicort, Arimidex, Seroquel, and Synagis - accounted for over 60% of the company's $32.8 billion in total sales. AZN has experienced continued sales and earnings growth in recent years and maintains a strong balance sheet and profitability ratios above historical averages.

    Original Description:

    An analysis of AstraZeneca plc

    Copyright

    © Attribution Non-Commercial (BY-NC)

    Available Formats

    DOCX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    AstraZeneca (AZN) is a major player in the biotechnology and drug industry with a rich product line focusing on six healthcare areas. In fiscal year 2009, AZN's top drugs - Nexium, Crestor, Symbicort, Arimidex, Seroquel, and Synagis - accounted for over 60% of the company's $32.8 billion in total sales. AZN has experienced continued sales and earnings growth in recent years and maintains a strong balance sheet and profitability ratios above historical averages.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    120 views1 page

    Astrazeneca Summary

    Uploaded by

    sommer_ronald5741
    AstraZeneca (AZN) is a major player in the biotechnology and drug industry with a rich product line focusing on six healthcare areas. In fiscal year 2009, AZN's top drugs - Nexium, Crestor, Symbicort, Arimidex, Seroquel, and Synagis - accounted for over 60% of the company's $32.8 billion in total sales. AZN has experienced continued sales and earnings growth in recent years and maintains a strong balance sheet and profitability ratios above historical averages.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    You are on page 1of 1

    The biotechnology and drug industry has come a long way in recent years.

    Formally filled with small, one


    product companies without sales and earnings, the industry now has major players. AstraZeneca (New
    York: AZN) is one such player.

    AZN has a rich product line focusing on six areas of healthcare: gastrointestinal, cardiovascular,
    respiratory, oncology, neuroscience and infection. The leading drugs in each category are: Nexium,
    Crestor, Symbicort, Arimidex, Seroquel, and Synagis, respectively.

    For FY 2009, Nexium accounted for approximately 15% of sales; Crestor 14%; Symbicort 7%, Arimidex
    6%, Seroquel 15% and Synagis 3%. Total sales for FY 2009 totaled $32,804 billion.

    Despite the difficult worldwide financial situation, AZN continues to grow. Sales for the 12 month period
    ending 03/10 grew 6.5%. For 1Q10, sales grew 11% over the year-ago period. Long term, sales grow at
    more than 7%.

    Earnings growth remains robust. EPS basic grew at the rate of 21.1% during the 12 month period ending
    03/10. In 1Q10, EPS grew 28% to $1.90 as compared to $1.48 in 1Q09. Long term, EPS is growing at
    about 19.9%.

    The company consistently reports positive free cash flow and pays a dividend of $3.42 per share. At a
    recent trading price of $48.79, the dividend yield is about 7.0%.

    AZN has a strong balance sheet. Cash and short term investments total $9,396.0 billion. Long term debt
    is $9,055.0 billion.

    On a valuation basis, the shares of AZN look very cheap particularly when compared to its peers. The PE
    TTM is 8.7X trailing earnings of $5.61 and 7.8X estimated 2010 earnings of $6.29. Five analysts follow
    AZN. Their earnings estimates range from a low of $6.25 to a high of $6.31. This very tight range
    indicates a very high confidence level for the estimates. We estimate EV/EBITDA to be about 6.5X.

    Looking at profitability ratios, we see strength. The current ROE at 41.5% exceeds the long term average
    ROE of 34.28%. Gross margin is at 82.0% is down only slightly from FY09 when the gross margin was
    83%. The gross margin remains significantly about the long term average of 79.23%.

    Similarly, operating margins are better now than in the past. The most recently reported operating
    margin is 35.7%, slightly better than FY09 and dramatically better than the long term average of 25.98%.

    Disclosure: Author is long AZN.

    You might also like